title: Topical treatment of basal cell carcinoma with the immune response modifier imiquimod.
abstract: Imiquimod, a TLR7 agonist, is a novel immune response modifier currently widely used in the treatment of actinic keratoses (in situ squamous cell carcinoma). Imiquimod has revolutionized the treatment of field cancerization and has been approved for the treatment of superficial basal cell carcinoma with the recommendation of a 6-week treatment strategy, offering an alternative to surgery or other destructive treatment strategies.
authors.affiliation: Department of Dermatology & Venerology, A Syggros Hospital, University of Athens, Medical School, 5, I. Dragoumi Str. 16121 Athens, Greece.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Papakostas
authors.affiliation: Department of Dermatology, Venerology & Allergology, Catholic Clinic Bochum, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44971 Bochum, Germany.
authors.forename: Eggert
authors.initials: E
authors.lastname: Stockfleth
mesh_terms: D000287:Administration, Topical; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D006801:Humans; D000077271:Imiquimod; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics; D009367:Neoplasm Staging; D011358:Product Surveillance, Postmarketing; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000634:Aminoquinolines; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000077271:Imiquimod
keywords: 5-FU; BCC nevus syndrome; Hedgehog signaling cascade; Mohs surgery; Toll-like receptor; actinic keratosis; basal cell carcinoma; condylomata accuminata; cytokines; field cancerization; imiquimod; immunosuppression; inflammation; interferon; nonmelanoma skin cancer; organ transplantation; photodynamic therapy; radiation; skin aging; sun exposure